Top Page
Ping An Healthcare and Technology Company
(1833)
Ping An Healthcare and Technology Company (1833) vs. iShares MSCI Hong Kong ETF (EWH)
Ping An Healthcare and Technology Company Business Overview & Revenue Model
Ping An Healthcare and Technology Company Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.22B | 4.81B | 4.67B | 6.21B | 7.33B | 6.87B |
| Gross Profit | 1.69B | 1.52B | 1.51B | 1.67B | 1.71B | 1.86B |
| EBITDA | 332.77M | 193.43M | -164.23M | -1.05B | -1.76B | -605.20M |
| Net Income | 158.94M | 81.43M | -322.59M | -636.06M | -1.54B | -948.48M |
Balance Sheet | ||||||
| Total Assets | 12.95B | 16.78B | 16.52B | 17.14B | 17.88B | 18.56B |
| Cash, Cash Equivalents and Short-Term Investments | 7.76B | 11.52B | 11.35B | 10.14B | 10.14B | 13.53B |
| Total Debt | 45.97M | 45.00M | 93.61M | 176.49M | 201.29M | 113.97M |
| Total Liabilities | 3.26B | 13.20B | 3.25B | 3.68B | 3.79B | 2.71B |
| Stockholders Equity | 9.70B | 3.59B | 13.28B | 13.46B | 14.08B | 15.83B |
Cash Flow | ||||||
| Free Cash Flow | 270.60M | 65.08M | -325.82M | -845.05M | -1.49B | -1.18B |
| Operating Cash Flow | 297.89M | 99.33M | -282.86M | -810.62M | -1.40B | -1.10B |
| Investing Cash Flow | 3.49B | 114.65M | -1.49B | 1.71B | -3.10B | -2.50B |
| Financing Cash Flow | -3.94B | -38.44M | -67.36M | -317.88M | -319.91M | 6.92B |
Ping An Healthcare and Technology Company Technical Analysis
Ping An Healthcare and Technology Company Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$22.89B | 39.61 | 24.57% | 0.68% | 13.58% | 24.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$336.00M | ― | -35.99% | ― | -5.38% | 63.93% | |
45 Neutral | $30.02B | 143.94 | 1.37% | 40.01% | 14.56% | ― | |
41 Neutral | HK$15.99B | -20.94 | -15.75% | ― | 102.73% | 38.42% | |
41 Neutral | HK$5.08B | ― | -2.97% | ― | -12.31% | 41.72% | |
40 Neutral | HK$1.17B | -6.52 | -12.97% | ― | -32.17% | -1.20% |
Ping An Healthcare and Technology Company Corporate Events
Ping An Healthcare and Technology Company Limited, a key player in the healthcare technology sector, focuses on integrating insurance with healthcare services to provide comprehensive health management solutions. The company recently reported a 13.6% increase in revenue for the nine months ending September 2025, reaching RMB 3.72 billion, alongside a significant 72.6% rise in net profit compared to the previous year. This growth is attributed to the company’s strategic focus on enhancing its insurance and healthcare synergies, expanding its corporate health management business, and leveraging AI technologies to improve service efficiency and quality. Notably, the company saw a 21.5% increase in revenue from its corporate health management business and a 30.6% rise in B-end paying users. Additionally, the family doctor membership surpassed 40 million, and the home-based senior care service user base grew by 41%. Looking forward, Ping An Healthcare plans to continue strengthening its collaboration with Ping An Group and advancing the digitalization and AI integration of its services to enhance user experience and satisfaction.
Ping An Healthcare and Technology Company Limited has established a Sustainable Development Committee under its Board of Directors to enhance corporate governance and address environmental, social, and governance (ESG) responsibilities. This initiative aims to align the company’s operations with sustainable practices, ensuring that its ESG policies remain relevant and effectively implemented, thereby potentially improving its industry positioning and stakeholder relations.
The most recent analyst rating on (HK:1833) stock is a Hold with a HK$16.50 price target. To see the full list of analyst forecasts on Ping An Healthcare and Technology Company stock, see the HK:1833 Stock Forecast page.
Ping An Healthcare and Technology Company Limited reported a 13.6% increase in revenue and a 45.7% rise in adjusted net profit for the first nine months of 2025, driven by the expansion of its insurance and healthcare synergies and corporate health management business. The company enhanced its AI capabilities, improving service quality and efficiency, and expanded its user base for family doctor and home-based senior care services, reflecting its strategic focus on integrating online and offline healthcare solutions.
The most recent analyst rating on (HK:1833) stock is a Hold with a HK$16.50 price target. To see the full list of analyst forecasts on Ping An Healthcare and Technology Company stock, see the HK:1833 Stock Forecast page.
Ping An Healthcare and Technology Company Limited has announced a board meeting scheduled for October 23, 2025, to review and approve the unaudited third quarterly results for the nine months ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1833) stock is a Sell with a HK$5.90 price target. To see the full list of analyst forecasts on Ping An Healthcare and Technology Company stock, see the HK:1833 Stock Forecast page.
Ping An Healthcare and Technology Company Limited has announced a significant leadership change with the resignation of Mr. Dou Li as Chairman, Executive Director, and CEO, effective October 7, 2025, due to personal work arrangements. Mr. Michael Guo, a non-executive director with extensive experience in the Ping An Group, has been appointed as the new Chairman, while Mr. Mingke He, who brings a wealth of experience from various industries, has been appointed as the new CEO and Executive Director. These changes are expected to maintain the company’s operational stability and continue its efficient corporate governance.
The most recent analyst rating on (HK:1833) stock is a Sell with a HK$5.90 price target. To see the full list of analyst forecasts on Ping An Healthcare and Technology Company stock, see the HK:1833 Stock Forecast page.
Ping An Healthcare and Technology Company Limited has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement may impact the company’s governance and strategic direction, potentially influencing its market positioning and stakeholder relations.
The most recent analyst rating on (HK:1833) stock is a Sell with a HK$5.90 price target. To see the full list of analyst forecasts on Ping An Healthcare and Technology Company stock, see the HK:1833 Stock Forecast page.
Ping An Healthcare and Technology Company Limited, a key player in the health and senior care sector, operates as a flagship of Ping An Group, providing comprehensive health services through an integrated online and offline network. In its latest earnings report for the first half of 2025, the company showcased robust financial growth and strategic advancements, driven by strengthened synergies with Ping An Group and significant improvements in profitability. Key highlights include a 19.5% increase in revenue to RMB2,502.2 million, a notable rise in gross profit by 24.6%, and a substantial boost in net profit attributable to shareholders by 136.8% year-on-year. The company also reported significant advancements in AI technology, enhancing its service capabilities and operational efficiency. Looking ahead, Ping An Healthcare aims to further leverage its synergies with Ping An Group and expand its service offerings, positioning itself as China’s leading online healthcare service portal.
Ping An Healthcare and Technology Company Limited announced that its subsidiary, Glorious Delight Limited, has entered into a discretionary account management agreement with China Life Franklin Asset Management Co., Ltd. This agreement, effective from August 19, 2025, appoints China Life Franklin as the discretionary investment manager for a total principal amount of up to USD 55 million over three years. The transaction aims to enhance the company’s return on capital and optimize the use of its surplus cash reserves. The agreement allows China Life Franklin to manage the investment portfolio with the objective of maximizing total returns, focusing on bonds, commercial paper, certificates of deposits, cash, cash equivalents, or money market instruments.
The most recent analyst rating on (HK:1833) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Ping An Healthcare and Technology Company stock, see the HK:1833 Stock Forecast page.
Ping An Healthcare and Technology Company Limited announced its unaudited interim results for the six months ending June 30, 2025. The results have been reviewed by the company’s audit and risk management committee and will be available on the company’s and the Stock Exchange’s websites. This announcement reflects the company’s compliance with listing requirements and provides stakeholders with insights into its financial performance during the first half of the year.
The most recent analyst rating on (HK:1833) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Ping An Healthcare and Technology Company stock, see the HK:1833 Stock Forecast page.
Ping An Healthcare and Technology Company Limited has announced a board meeting scheduled for August 19, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the declaration and payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.
The most recent analyst rating on (HK:1833) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Ping An Healthcare and Technology Company stock, see the HK:1833 Stock Forecast page.